Aptevo Therapeutics (APVO) Current Assets (2015 - 2026)
Aptevo Therapeutics (APVO) posted Current Assets of $16.0 million for Q1 2026, down 30.75% sequentially from $23.1 million in Q4 2025, and up 343.14% YoY from $3.6 million in Q1 2025.
Aptevo Therapeutics (APVO) Current Assets (2015 - 2026) Analysis & Trends
Aptevo Therapeutics has reported Current Assets for 12 years, with the latest figure at $16.0 million in Q1 2026.
- Quarterly Current Assets rose 343.14% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.0 million (up 343.14% YoY) and the FY2025 annual result came in at $23.1 million, up 116.54% from the prior year.
- Current Assets retreated to $16.0 million in Q1 2026 per APVO's latest filing, from $23.1 million in the prior quarter.
- Over five years, Current Assets peaked at $41.7 million in Q1 2022 and troughed at $3.6 million in Q1 2025.
- A 5-year average of $19.7 million and a median of $21.1 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2025 and 2026: Current Assets tumbled 70.13% in 2025, then surged 343.14% in 2026.
- Over 5 years, Current Assets stood at $27.4 million in 2022, then sank by 30.54% to $19.1 million in 2023, then slumped by 44.09% to $10.7 million in 2024, then soared by 116.54% to $23.1 million in 2025, then slumped by 30.75% to $16.0 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $16.0 million, $23.1 million, and $22.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | Aptevo Therapeutics | 3.18 Mn | -6.61 Mn | - | 10.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.80 Mn |
| Mar 31, 2026 | 15.98 Mn |
| Dec 31, 2025 | 23.08 Mn |
| Sep 30, 2025 | 22.65 Mn |
| Jun 30, 2025 | 11.08 Mn |
| Mar 31, 2025 | 3.61 Mn |
| Dec 31, 2024 | 10.66 Mn |
| Sep 30, 2024 | 10.01 Mn |
| Jun 30, 2024 | 9.58 Mn |
| Mar 31, 2024 | 12.07 Mn |
| Dec 31, 2023 | 19.07 Mn |
| Sep 30, 2023 | 21.13 Mn |
| Jun 30, 2023 | 22.68 Mn |
| Mar 31, 2023 | 28.49 Mn |
| Dec 31, 2022 | 27.45 Mn |
| Sep 30, 2022 | 24.62 Mn |
| Jun 30, 2022 | 31.40 Mn |
| Mar 31, 2022 | 41.67 Mn |
| Dec 31, 2021 | 52.57 Mn |
| Sep 30, 2021 | 58.87 Mn |